Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

This study is testing whether a lower dose of radiation to a specific area (the low-risk clinical target volume) during treatment for nasopharyngeal carcinoma (a cancer at the back of the nose and throat) is just as effective as the standard dose — potentially reducing side effects without compromising outcomes. **You may be eligible if...** - You are 18–70 years old with a newly diagnosed, untreated nasopharyngeal carcinoma that has not spread to distant organs - Your blood counts, kidney function, and liver function meet the required thresholds - Your overall health is good (ECOG score 0–1) **You may NOT be eligible if...** - You have previously received chemotherapy, surgery (other than biopsy), or radiation to the head and neck - You have had another cancer before (with some exceptions like treated skin cancer) - Your cancer has spread to distant sites in the body Talk to your doctor to see if this trial is right for you.